Certara

“𝗦𝗵𝗼𝘄 𝗺𝗲 𝘁𝗵𝗲 𝗱𝗮𝘁𝗮.” 𝗧𝗵𝗮𝘁’𝘀 𝘄𝗵𝗮𝘁 𝗶𝗻𝘃𝗲𝘀𝘁𝗼𝗿𝘀 𝘄𝗮𝗻𝘁 𝘁𝗼 𝗵𝗲𝗮𝗿 𝗯𝗲𝗳𝗼𝗿𝗲 𝗮𝗻𝘆 𝗱𝗲𝗮𝗹 𝗺𝗼𝘃𝗲𝘀 𝗳𝗼𝗿𝘄𝗮𝗿𝗱. But proving your asset’s true potential requires more than spreadsheets — it requires a model-informed strategy. Join Fran Brown, PhD, Senior Vice President S. Y. Amy Cheung, PhD, Vice President, as they reveal how 𝗠𝗼𝗱𝗲𝗹-𝗜𝗻𝗳𝗼𝗿𝗺𝗲𝗱 𝗗𝗿𝘂𝗴 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 (𝗠𝗜𝗗𝗗) quantifies risk, predicts clinical performance, and supports transparent due diligence. Yu-Wei Wayne Lin, Director, will address these same topics during the APAC webinar. ✅ Strengthen negotiations ✅ Build confidence in valuations ✅ De-risk development decisions 𝗨𝗦: November 6 | 11:00–11:30 AM EST 𝗘𝗠𝗘𝗔: November 13 | 10:00–11:00 AM UK 𝗔𝗣𝗔𝗖: November 20 | 10:00 AM – 10:30 AM JST Secure your spot! https://ow.ly/MMJv50XaNer #MIDD #BiotechInvestment #ClinicalDevelopment #Certara

We’re excited to join DIA Canada 2025 in Gatineau, QC! 📅 𝗢𝗰𝘁𝗼𝗯𝗲𝗿 𝟮𝟴 🕐 12:45–2:00 PM – 𝘋𝘦𝘷𝘪𝘴𝘦 𝘌𝘧𝘧𝘦𝘤𝘵𝘪𝘷𝘦 𝘙𝘦𝘨𝘶𝘭𝘢𝘵𝘰𝘳𝘺 𝘚𝘵𝘳𝘢𝘵𝘦𝘨𝘺: 𝘜𝘴𝘪𝘯𝘨 𝘵𝘩𝘦 𝘓𝘦𝘯𝘴 𝘰𝘧 𝘙𝘦𝘨𝘶𝘭𝘢𝘵𝘰𝘳𝘺 𝘐𝘯𝘵𝘦𝘭𝘭𝘪𝘨𝘦𝘯𝘤𝘦 🕑 2:10–3:25 PM – 𝘌𝘮𝘣𝘳𝘢𝘤𝘪𝘯𝘨 𝘈𝘐: 𝘗𝘳𝘢𝘤𝘵𝘪𝘤𝘢𝘭 𝘈𝘱𝘱𝘳𝘰𝘢𝘤𝘩𝘦𝘴 𝘵𝘰 𝘛𝘳𝘢𝘯𝘴𝘧𝘰𝘳𝘮𝘪𝘯𝘨 𝘊𝘭𝘪𝘯𝘪𝘤𝘢𝘭, 𝘙𝘦𝘨𝘶𝘭𝘢𝘵𝘰𝘳𝘺 𝘈𝘧𝘧𝘢𝘪𝘳𝘴 & 𝘗𝘰𝘴𝘵-𝘈𝘱𝘱𝘳𝘰𝘷𝘢𝘭 𝘈𝘤𝘵𝘪𝘷𝘪𝘵𝘪𝘦𝘴 Join Dr. Anaya Rehman, MD, MS as she leads two sessions exploring how regulatory intelligence and AI are transforming drug development and regulatory strategy. Learn more and meet Anaya at DIA Canada ➡️ https://ow.ly/o1xo50Xenvo #DIACanada #Certara #RegulatoryScience #CertaraRegWrites #CertaraRegSci

𝗗𝗮𝘆 𝗧𝘄𝗼 𝗮𝘁 #𝗔𝗖𝗼𝗣𝟮𝟬𝟮𝟱 — 𝗦𝗰𝗶𝗲𝗻𝗰𝗲, 𝗦𝘁𝗿𝗮𝘁𝗲𝗴𝘆 & 𝗦𝘁𝗮𝗻𝗱𝗶𝗻𝗴 𝗥𝗼𝗼𝗺 𝗢𝗻𝗹𝘆! What a day for #TeamCertara at ACoP! From highly attended sessions to lively booth demos, our scientists and modelers brought Model-Informed Drug Development (#MIDD) to life across disciplines. 𝗜𝗻 𝘁𝗵𝗲 𝘀𝗽𝗼𝘁𝗹𝗶𝗴𝗵𝘁: Sibylle Neuhoff shared insights on how PBPK-PD modeling can accelerate drug development for obese and other special populations — a perfect example of using physiology-driven science to tackle real-world diversity. Douglas Chung joined the panel on #QSP modeling in autoimmune disease, highlighting how mechanistic modeling and machine learning can predict complex immune responses and clinical scores. Matt Zierhut chaired the standing-room-only session on Model-Based Meta-Analysis (#MBMA), where data integration and quantitative insights are reshaping how decisions are made in clinical development. At the booth, we kept the energy going with demos of 𝗖𝗲𝗿𝘁𝗮𝗿𝗮 𝗜𝗤™, 𝗣𝗵𝗼𝗲𝗻𝗶𝘅® 𝗖𝗹𝗼𝘂𝗱, 𝗦𝗶𝗺𝗰𝘆𝗽™, 𝗮𝗻𝗱 𝗖𝗢𝗗𝗘𝗫 𝗔𝗻𝗮𝗹𝘆𝘁𝗶𝗰𝘀— sparking great conversations about scaling modeling, integrating data, and accelerating smarter decisions. A huge thank-you to our presenters, partners, and everyone who stopped by to connect. Your curiosity, questions, and collaboration keep pushing the field forward. #ACoP2025 #ModelInformedDrugDevelopment #PBPK #QSP #MBMA #Pharmacokinetics #QuantitativePharmacology #DrugDevelopment #MIDD

𝐒𝐜𝐢𝐞𝐧𝐜𝐞 𝐰𝐢𝐭𝐡 𝐕𝐢𝐬𝐢𝐨𝐧: 𝐂𝐞𝐥𝐞𝐛𝐫𝐚𝐭𝐢𝐧𝐠 𝐃𝐫. 𝐀𝐦𝐢𝐧 𝐑𝐨𝐬𝐭𝐚𝐦𝐢-𝐇𝐨𝐝𝐣𝐞𝐠𝐚𝐧’𝐬 𝐄𝐧𝐝𝐮𝐫𝐢𝐧𝐠 𝐈𝐦𝐩𝐚𝐜𝐭 Behind every scientific breakthrough is a mind that dares to question assumptions and bridge complexity with clarity. At Certara, we’re proud to celebrate Amin Rostami-Hodjegan, Chief Scientific Officer, for receiving this year’s 𝑳𝒆𝒘𝒊𝒔 𝑩. 𝑺𝒉𝒆𝒊𝒏𝒆𝒓 𝑳𝒆𝒄𝒕𝒖𝒓𝒆 award—a distinction reserved for those who redefine how we understand and advance pharmacometrics. For decades, Amin has championed the integration of physiology, data, and imagination to better predict how medicines behave across diverse patients—redefining pharmacokinetics as a story of human variability, not just numbers. His leadership has inspired hundreds of scientists to model smarter, think deeper, and design safer, more effective therapies—creating a ripple effect that continues to improve lives worldwide. Congratulations, Amin, and thank you for leading with vision, curiosity, and heart. Your legacy lives not only in your models, but in the people and progress you’ve inspired. #ACoP2025 #ISoP #Pharmacometrics #PrecisionMedicine #PatientVariability #DrugDevelopment #Leadership #QuantitativePharmacology #Innovation #Certara

What a kickoff to #ACoP2025! We introduced 𝗖𝗲𝗿𝘁𝗮𝗿𝗮 𝗜𝗤™, AI-powered Quantitative Systems Pharmacology (#QSP) solution that scales modeling across entire pipelines in a hands on pre-conference workshop — led by Josh Apgar, Matteson, Sasha Shirman, Douglas Chung, Kimiko McGirr, PhD, Piet van der Graaf, and Dennis Reddyhoff. And Hannah Jones, delivered an impactful talk on how #PBPK modeling accelerates first-in-human studies and regulatory submissions. If you’re attending ACoP2025 stop by Booth #17 & #18 to meet the team and check out our demos. View our full lineup of activities: https://lnkd.in/eHR35k4Y. 𝗖𝘂𝗿𝗶𝗼𝘂𝘀 𝘁𝗼 𝘀𝗲𝗲 𝗖𝗲𝗿𝘁𝗮𝗿𝗮 𝗜𝗤™ 𝗶𝗻 𝗮𝗰𝘁𝗶𝗼𝗻? Join our webinar on October 30 for an inside look at how 𝗖𝗲𝗿𝘁𝗮𝗿𝗮 𝗜𝗤™ blends AI and cloud-powered QSP modeling to drive smarter, faster decisions. 𝙍𝙚𝙜𝙞𝙨𝙩𝙚𝙧 𝙝𝙚𝙧𝙚: https://lnkd.in/ewjNQsum A huge thank you to everyone who joined us today — your energy made for an incredible start to #ACoP2025! #CertaraIQ #QSP #PBPK #ModelingAndSimulation #MIDD #Pharmacometrics #DrugDevelopment #DrugDiscovery #ClinicalPharmacology

Join Certara at 𝗝𝗦𝗦𝗫 𝟮𝟬𝟮𝟱, October 21–23 in 𝗞𝘆𝗼𝘁𝗼, 𝗝𝗮𝗽𝗮𝗻! Visit Booth 18 to meet our Japan team and explore the latest in 𝗣𝗕𝗣𝗞 𝗮𝗻𝗱 𝗣𝗞/𝗣𝗗 𝗺𝗼𝗱𝗲𝗹𝗶𝗻𝗴 & 𝘀𝗶𝗺𝘂𝗹𝗮𝘁𝗶𝗼𝗻. 📢 𝗗𝗼𝗻’𝘁 𝗺𝗶𝘀𝘀 𝗼𝘂𝗿 𝗽𝗿𝗲𝘀𝗲𝗻𝘁𝗮𝘁𝗶𝗼𝗻 & 𝗽𝗼𝘀𝘁𝗲𝗿 𝘀𝗲𝘀𝘀𝗶𝗼𝗻: - QSP modeling of ADCs: case studies using Kadcyla and Enhertu — Kimiko McGirr, PhD - Use of PBPK model to investigate the impact of daily breastfeeding frequency on tenofovir exposure in breastfed infants — Jia Ning, PhD Let’s connect and discuss how Certara’s modeling and simulation technologies are shaping the future of drug development! https://ow.ly/ngR850Xebmn #JSSX2025 #Certara #PBPK #QSP #PK/PD #MIDD

𝗔𝗖𝗼𝗣 𝟮𝟬𝟮𝟱 𝗶𝘀 𝗛𝗘𝗥𝗘 — 𝗦𝗲𝗲 𝗬𝗼𝘂 𝗶𝗻 𝗔𝘂𝗿𝗼𝗿𝗮! We’re heading to Aurora, Colorado for #ACoP2025, and we couldn’t be more excited to connect, collaborate, and celebrate innovation in Model-Informed Drug Development (#MIDD). 𝗝𝗼𝗶𝗻 𝗨𝘀 Hear from our experts during sessions and workshops as they share the latest advances in Quantitative Systems Pharmacology (#QSP), Pharmacokinetics/Pharmacodynamics (PK/PD), Artificial Intelligence (AI)-enabled modeling, and beyond. 𝗖𝗲𝗹𝗲𝗯𝗿𝗮𝘁𝗲 𝘄𝗶𝘁𝗵 𝗨𝘀 Congratulations to Amin Rostami-Hodjegan, PhD, Chief Scientific Officer at Certara and Director of CAPKR, The University of Manchester! Amin will receive the 𝟮𝟬𝟮𝟱 𝗟𝗲𝘄𝗶𝘀 𝗕. 𝗦𝗵𝗲𝗶𝗻𝗲𝗿 𝗟𝗲𝗰𝘁𝘂𝗿𝗲𝗿 𝗔𝘄𝗮𝗿𝗱 on Saturday at 6 PM, honoring his innovative impact on research, drug development, and regulatory science. He’ll deliver his lecture, “𝑇𝑎𝑘𝑖𝑛𝑔 𝑜𝑛 𝐶𝑟𝑎𝑐𝑘𝑠 𝑂𝑛𝑙𝑦 𝑡𝑜 𝑆𝑒𝑒 𝐵𝑖𝑔𝑔𝑒𝑟 𝐺𝑎𝑝𝑠: 𝐴𝑑𝑑𝑟𝑒𝑠𝑠𝑖𝑛𝑔 𝑃𝑎𝑡𝑖𝑒𝑛𝑡 𝑉𝑎𝑟𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 𝑖𝑛 𝑃ℎ𝑎𝑟𝑚𝑎𝑐𝑜𝑘𝑖𝑛𝑒𝑡𝑖𝑐𝑠.” 𝗩𝗶𝘀𝗶𝘁 𝘂𝘀 𝗮𝘁 𝗕𝗼𝗼𝘁𝗵 #𝟭𝟳 & 𝟭𝟴 Experience live demos, deep-dive discussions, and a firsthand look at next-generation tools including Certara IQ™ (our NEW AI-enabled, cloud-based SaaS platform), Phoenix® Cloud, Simcyp™, CODEX Analytics, and more. 𝗗𝗼𝗻’𝘁 𝗺𝗶𝘀𝘀 𝗼𝘂𝗿 𝘄𝗼𝗿𝗸𝘀𝗵𝗼𝗽𝘀: • 𝑄𝑆𝑃 𝑎𝑡 𝑆𝑐𝑎𝑙𝑒 𝑤𝑖𝑡ℎ 𝐶𝑒𝑟𝑡𝑎𝑟𝑎 𝐼𝑄™ – 𝑟𝑒𝑑𝑒𝑓𝑖𝑛𝑖𝑛𝑔 𝑚𝑜𝑑𝑒𝑙𝑖𝑛𝑔 𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 𝑎𝑛𝑑 𝑠𝑐𝑎𝑙𝑎𝑏𝑖𝑙𝑖𝑡𝑦 • 𝑀𝑜𝑑𝑒𝑙-𝐵𝑎𝑠𝑒𝑑 𝑀𝑒𝑡𝑎-𝐴𝑛𝑎𝑙𝑦𝑠𝑖𝑠 (#𝑀𝐵𝑀𝐴): 𝐶𝑜𝑛𝑐𝑒𝑝𝑡𝑠, 𝑀𝑒𝑡ℎ𝑜𝑑𝑜𝑙𝑜𝑔𝑖𝑒𝑠, 𝑎𝑛𝑑 𝐻𝑎𝑛𝑑𝑠-𝑜𝑛 𝑊𝑜𝑟𝑘𝑠ℎ𝑜𝑝 – 𝑒𝑥𝑝𝑙𝑜𝑟𝑖𝑛𝑔 𝑑𝑎𝑡𝑎 𝑖𝑛𝑡𝑒𝑔𝑟𝑎𝑡𝑖𝑜𝑛 𝑎𝑛𝑑 𝑞𝑢𝑎𝑛𝑡𝑖𝑡𝑎𝑡𝑖𝑣𝑒 𝑑𝑒𝑐𝑖𝑠𝑖𝑜𝑛-𝑚𝑎𝑘𝑖𝑛𝑔 Whether you’re a seasoned modeler or new to the field, stop by to chat, explore, and see how Certara is shaping the future of drug development. 𝗩𝗶𝗲𝘄 𝗼𝘂𝗿 𝗳𝘂𝗹𝗹 𝗔𝗖𝗼𝗣 𝟮𝟬𝟮𝟱 𝗹𝗶𝗻𝗲𝘂𝗽: https://ow.ly/5t3550Xebfa #ACoP2025 #Certara #ModelInformedDrugDevelopment #QSP #PKPD #AIinPharma #Biosimulation #Pharmacometrics #ISoP

𝗤𝗦𝗣-𝗕𝗮𝘀𝗲𝗱 𝗩𝗶𝗿𝘁𝘂𝗮𝗹 𝗧𝘄𝗶𝗻® 𝗧𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝘆 𝗳𝗼𝗿 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 𝗶𝗻 𝗥𝗮𝗿𝗲 𝗗𝗶𝘀𝗲𝗮𝘀𝗲𝘀 Did you miss our latest webinar? Now available to watch on-demand: https://ow.ly/mxW250Xe778 This session covers key topics, including: - How 𝗩𝗶𝗿𝘁𝘂𝗮𝗹 𝗧𝘄𝗶𝗻 𝗺𝗼𝗱𝗲𝗹𝘀 are transforming rare disease therapy development, with an ASMD use case. - A compelling 𝗣𝗼𝗺𝗽𝗲 𝗗𝗶𝘀𝗲𝗮𝘀𝗲 𝗰𝗮𝘀𝗲 𝘀𝘁𝘂𝗱𝘆, showcasing streamlined and efficient drug development. - Innovative strategies for tackling challenges in 𝗿𝗮𝗿𝗲 𝗱𝗶𝘀𝗲𝗮𝘀𝗲𝘀 𝗮𝗻𝗱 𝗴𝗲𝗻𝗲 𝘁𝗵𝗲𝗿𝗮𝗽𝘆 𝘁𝗿𝗶𝗮𝗹𝘀, especially for small patient populations. 👉 Watch on-demand today: https://ow.ly/mxW250Xe778 #QSP #VirtualTwin #QuantitativeSystemsPharmacology #RareDiseaseResearch #DigitalTwins #VirtualPatients #PrecisionMedicine

Certainty Discovery 2025 - Join leading minds in drug discovery and cheminformatics.

We had an amazing time at the 25th Safety Pharmacology Society Annual Meeting! Our team shared innovative in silico approaches that advance preclinical safety. Highlights from the event: • Piet van der Graaf, PhD, SVP and Head of QSP at Certara, delivered the keynote presentation, highlighting the evolution of QSP and its impact on safety pharmacology with case studies in cardiac and hemodynamic safety, T-cell engagers, and ADCs. • Hiba Khalidi, PhD, Research Scientist at Certara, received the SPS Junior Investigator Travel Award. • QSTS experts, Will Redfern PhD, Chris Pollard, and Mutra Abbasi, collectively presented four posters showcasing the application of predictive toxicology software to identify risks earlier on. We’re proud to contribute to advancing safer and more effective drug development. • Learn more about Certara’s QSP capabilities: https://ow.ly/Tn8A50XcHIm • Explore Certara ToxStudio our predictive toxicology software platform: https://ow.ly/qLJC50XcHIl